Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Not Available].

J A Balfour1, P Benfield

  • 1Adis International Limited, Auckland, New Zealand.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Rimexolone, a nonfluorinated glucocorticoid, offers prolonged intra-articular residence and minimal skin effects. It provides long-lasting relief for rheumatoid arthritis and osteoarthritis patients with few systemic impacts.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Moclobemide: An update of its pharmacological properties and therapeutic use.

Drugs·2017
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Levetiracetam.

CNS drugs·2013
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Combination hepatitis a-hepatitis B vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Pharmacology and Rheumatology
  • Musculoskeletal and Joint Diseases

Background:

  • Glucocorticoids are widely used for inflammatory joint conditions.
  • Systemic absorption and skin atrophy are common side effects of topical steroids.
  • Need for locally active corticosteroids with improved safety and efficacy profiles.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetic profile of rimexolone, a novel nonfluorinated glucocorticoid.
  • To compare rimexolone's intra-articular residence time and clinical outcomes against other corticosteroid preparations.

Main Methods:

  • Assessment of intra-articular residence time following injection.
  • Evaluation of serum concentrations and local skin effects.
  • Clinical trials in patients with rheumatoid arthritis and osteoarthritis.

Related Experiment Videos

Main Results:

  • Rimexolone demonstrated the longest intra-articular residence time (25 days) compared to other steroids.
  • Minimal systemic absorption and no significant atrophogenic effects on the skin were observed.
  • Single intra-articular injections of rimexolone provided sustained clinical improvement in arthritis patients.

Conclusions:

  • Rimexolone is a potent, locally acting glucocorticoid with a favorable safety profile for intra-articular use.
  • Its prolonged local action and minimal systemic effects make it a valuable therapeutic option for joint inflammation.
  • Rimexolone showed superiority over placebo and comparable or better efficacy than other corticosteroids in clinical studies.